BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus » Page 2

Capricor Treats Two COVID-19 Patients with Cardiosphere-Derived Cells (CAP-1002)

By

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy.

LOS ANGELES, April 03, 2020 — Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway. [Read more…]

NantKwest, ImmunityBio Advance BM-MSCs, NK Cell Therapies & Vaccines Against COVID-19

By

Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS).

  • Therapeutic for Severe and Critically Ill COVID-19 Patients on Ventilator Support:
    • NantKwest’s MSCs: Bone marrow-derived mesenchymal stem cells (MSC) to mitigate ‘cytopathic storm’ [Read more…]

Cure Alliance Launches 24-Patient Trial Using UC-MSCs Against COVID-19 Complications

By

FDA Authorizes Cure Alliance Rxperts to Test UC-MSCs

THE CURE ALLIANCE, April 9, 2020 — After a lightening round of proposals and reviews, an international team of scientists led by Dr. Camillo Ricordi was granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) to block the life-threatening lung inflammation that accompanies severe cases of COVID-19. [Read more…]

Orbsen’s COVID-19 Trial To Test Stromal Cell Immunotherapy Against ARDS

By

Orbsen’s stromal cell immunotherapy, ORBCEL, may benefit patients with Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus (COVID-19).

08 Apr, 2020, GALWAY, Ireland, April 8, 2020 — Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of best-in-class stromal cell immunotherapies, announced the beginning of a phase 2a clinical trial for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS). Nearly 90 percent of deaths caused by COVID-19 are the result of ARDS.

[Read more…]

COVID-19 Diagnostic Kits: Total Number, Types and Speed

By

As of today, 41 laboratory COVID-19 diagnostic tests have been authorized by regulators to identify the virus. In the U.S., these tests are supplied by the CDC for the state and local public health departments and private medical providers are getting tests developed by the commercial manufacturers. The U.S. government did not issue guidance allowing commercial labs to process COVID-19 tests until February 29, 2020, after which the companies began testing within a week.

Currently, 20 COVID-19 diagnostic kits from the U.S. manufacturers have won the emergency use authorization (EUA) from the FDA. [Read more…]

BioInformant's World-Class Clients